( . Inextremely minute quantities botul...)DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC,Health

. In extremely minute quantities, botulinum toxin can be used therapeutically, as for the cosmetic use of Botox®, a commercial preparation of serotype A botulinum toxin, but the effects of the neurotoxin are extremely long lasting and paralytic at higher than therapeutic doses.

About Botulinum Toxin Vaccines

Vaccination is considered the best option to prevent neurological effects of toxin exposure. Because of the rarity of the natural disease, a vaccine would not be used in mass population immunization programs unless they were actually used or a significant threat. In that event, the vaccine would have to be made available for widespread dissemination for rapid and convenient vaccination of a large population. The only vaccine available is an experimental vaccine based on inactivation of a mixture of serotypes of the natural toxins that is given by injection, is not licensed by the FDA and cannot be used for widespread immunization. New multivalent vaccines based on non-toxic subunits are being developed, including BT-VACC™.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal ("GI") diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI graft-versus-host disease ("GVHD"), a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA with the FDA for the treatment of GI GVHD, and has received a PDUFA date of July 21, 2007. An MAA with the EMEA for orBec® has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has also recently initiated a clinical development program with its Lipid Polymer Micelle
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis